secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0000950170-25-069301
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics Q1 net loss $18.2M; VMT-α-NET cohort enrollment reaches 40 patients
--------------------------------------------------------------------------------

- Net loss $18.2M ($0.25 loss per share) vs $12.3M loss in prior year; R&D spend +92% to $14.3M.
- Cash $212M as of March 31; expects funding into late 2026; sold $10.2M in ATM shares in Feb 2025 at ~$3.02/share.
- VMT-α-NET: 40 patients enrolled in Cohort 2 as of April 30; data accepted for oral ASCO 2025 presentation.
- VMT01: first patient treated at new monotherapy dose level (April 2025) and in combo with nivolumab (March 2025).
- PSV359: first patient dosed; three new U.S. manufacturing sites underway for future commercial demand.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000095017025069301/0000950170-25-069301-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000095017025069301/catx-20250512.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-069301

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer